References
- Center for Disease Control. Eosinophilia-myalgia syndrome and 1-tryptophan containing products–New Mexico, Minnesota, Oregon and New York. Morbidity & Mortality Weekly Report 1989a; 38: 785–788
- Center for Disease Control. Update: Eosinophilia-Myalgia Syndrome associated with ingestion of L-Tryptophan--United States. Morbidity & Mortality Weekly Report 1989b; 38: 842–843
- Center for Disease Control. Clinical Spectrum of Eosinophilia-Myalgia Syndrome--California. Morbidity & Mortality Weekly Report 1990a; 39: 89–91
- Center for Disease Control. Eosinophilia-Myalgia Syndrome--Canada. Morbidity & Mortality Weekly Report 1990b; 39: 326–327
- Dorfman L. J., Ransom B. R., Forno L. S., Kelts A. Neuropathy in the hypereosinophilic syndrome. Muscle & Nerve 1983; 6: 291–298
- Durack D. T., Ackerman S. J., Loegering D. A., Gleich G. J. Purification of human eosinophil-derived neurotoxin. The Proceedings of the National Academy of Sciences USA 1981; 78: 5165–5169
- Durack D. T., Sumi S. M., Klebanoff S. J. Neurotoxicity of human eosinophils. The Proceedings of the National Academy of Sciences USA 1979; 76: 1443–1447
- Fauci A. S., Harley J. B., Roberts W.C, Ferrans V. J., Gralnick H. R., Bjornson B. J. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Annals of Internal Medicine 1982; 97: 78–92
- Grisold W., Jellinger K. Multifocal neuropathy with vasculitis in hypereosinophilic syndrome. An entity or drug-induced effect. Journal of Neurology 1985; 231: 301–306
- Hertzman P. A., Blevins W. L., Mayer J., Greenfield B., Ting M., Bleich G. J. Association of the eosinophilia-myalgia syndrome with the ingestion of 1-tryptophan. New England Journal of Medicine 1990; 322: 869–873
- Kaplan, Waterbury P. W., Kawas L., Bolla-Wilson K., Durack D. Reversible dementia with idiopathic hypereosinophilic syndrome. Neurology 1989; 39: 1388–1391
- Martin R. W., Duffy J., Engel A. G., Lie J. T., Bowles C. A., Moyer T. P., Gleich G. J. The clinical spectrum of the eosinophilia-myalgia syndrome associated with 1-tryptophan ingestion. Annals of Internal Medicine 1990; 113: 124–134
- Medsger T. A. Tryptophan-induced eosinophilia-myalgia syndrome. New England Journal of Medicine 1990; 322: 926–928
- Moore P. M., Harley J. B., Fauci A. S. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Annals of Internal Medicine 1985; 102: 109–114
- Silver R. M., Heyes M. P., Maize J.C, Quearry B., Vionnet-Fausset M., Sternberg E. M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. New England Journal of Medicine 1990; 322: 874–881
- Slutsker L., Hoesly F.C, Miller L., Williams L. P., Watson J. C., Fleming D. W. Eosinophilia-myalgia syndrome associataed with exposure to tryptophan from a single manufacturer. Journal of the American Medical Association 1990; 264: 213–217
- Smith B. E., Dyck P. J. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with 1-tryptophan ingestion. Neurology 1990; 40: 1035–1040
- Tolander L. M., Bamford C. R., Yoshino M. T., Downing S., Bryan G. Neurological complications of the 1-tryptophan associated eosinophilia-myalgia syndrome. Archives of Neurology 1991; 48: 436–438
- Venge P., Dahl R., Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thrombosis Research 1979; 14: 641–649
- Weaver D. F., Heffernan L. P., Purdy R. A., Ing V. W. Eosinophil-induced neurotoxicity: Axonal neuropathy, cerebral infarction, and dementia. Neurology 1988; 38: 144–146